Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tavapadon + Trimethobenzamide Phase 1 in Healthy Volunteers
NCT02262767Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tavapadon in Parkinson's disease (PD) (2 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Supine and standing vital sign measurements and 2 more. Started Nov 2014; status: completed.
02
Drugs
tavapadon
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02262767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02262767.